Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
CRISLEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement...
Curis to Present at Upcoming Healthcare Conferences in September
CRIS(NASDAQ:CRIS) LEXINGTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis,...
HC Wainwright & Co. Assumes Curis at Buy, Announces Price Target of $17
CRISCuris Q1 EPS $(1.25) Misses $(0.87) Estimate, Sales $2.38M Miss $2.75M Estimate
CRISEarnings Outlook For Curis
CRIS12 Health Care Stocks Moving In Wednesday's Pre-Market Session
CRISHC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $16
CRISCuris Says Orphan Drug Designation For PCNSL Granted In U.S. And EU
CRISHC Wainwright & Co. Reiterates Buy on Curis, Maintains $20 Price Target
CRISCuris Q3 2024 GAAP EPS $(1.70) Beats $(1.83) Estimate, Cash And Cash Equivalents Of $31.6M Is Expected To Provide Cash Runway Into Mid-2025
CRISCuris 13G Filing Shows Thomas A. Satterfield, Jr. Reported A 8.05% Stake In The Co As Of October 30, 2024
CRISHC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $20
CRISEarnings Outlook For Curis
CRISCuris (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Curis will report an earnings per share (EPS) of $-0.16.
